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Purpose/Objective: There are a few reports of the radiotherapy for 
synchronous carcinomas in the head and neck (H&N) and esophagus. 
Purpose of this retrospective study is to analyze the results of 
definitive radiotherapy and find the possible prognostic factors. 
Materials and Methods: We reviewed the records of 48 patients with 
synchronous carcinoma in H&N and esophagus who were treated by 
definitive radiotherapy between 2000 and 2012 in our institution. The 
patients with distant metastasis were excluded in this study. 
Regarding head and neck carcinoma, the primary site was 
hypopharynx in 35 patients, larynx in 7, oropharynx in 3 and multiple 
primary sites in 3. Lymph node involvement was seen in 10 patients. 
Eighteen patients were classified to Stage I, 16 to Stage II, 6 to Stage 
III and 8 to Stage IV. Radiation dose in H&N ranged from 34Gy/17fr to 
70Gy/35fr with mean dose of 60Gy/30fr. Concerning esophageal 
carcinoma, single site in esophagus was involved in 23 patients and 
multiple sites in 25 patients. Lymph node metastasis was seen in 21 
patients. Twenty-four patients were classified to Stage I, 9 to Stage II, 
14 to Stage III and 1 to Stage IV. Radiation dose in esophagus ranged 
from 34Gy/17fr to 66Gy/33fr with mean dose of 60Gy/30fr. 
Concurrent 5-FU and cisplatin was administered to 41 patients, and 
the remaining 7 patients were treated by radiation alone. 
Results: The 3-year overall, and cause-specific survival rates were 
38.5% and 52.7% respectively. Advanced esophageal carcinoma stage 
(stage III or IV) had worse 3-year cause-specific survival rate than 
stage I or II esophageal carcinoma (63.8% vs. 24.4%, p=0.02).  
Concerning adverse events, 22 patients (45.8%) needed dmission 
management due to severe acute toxicity. Concurrent chemoradiation 
group had higher rate of admission than radiation alone group (51.2% 
vs. 14.3%). Eighteen patients (37.5%) experienced grade 3 or more 
chronic toxicity (CTCAE ver4.0). Five patients (10.4%) died from 
treatment related complications. 
Conclusions: Definitive concurrent chemoradiotherapy for 
synchronous carcinoma in H&N and esophagus may be a treatment 
option but intensity was so strong that the indication for large field 
radiotherapy and concurrent use of chemotherapy must be very 
cautiously considered. Advanced stage of esophageal carcinoma was 
worse prognostic factor for cause-specific survival rate. 
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Purpose/Objective: To evaluate the dose to carotid artery in patients 
treated with intensity modulated radiation therapy (IMRT) for 
oropharyngeal cancer.  
Materials and Methods: Ten patients with locally or regionally 
advanced oropharyngeal cancer were treated with IMRT. The primary 
tumour involvement was as follows: base of tongue (n=4), tonsil 
(n=2),vallecula (n=3), and soft palate (n=1). The TNM classification of 
the tumour was as follows: T2 (n=1), T3 (n=8), T4a (n=1), N0 (n=5), N1 
(n=2), N2b (n=1), N2c(n=2), and M0 (n=10). The planning CECT scan 
was obtained at 3 mm slice thickness. The right and left common, 
internal, and external carotid arteries were contoured from the level 
of sterno-clavicular joint to the base of skull. The following dose 
schedule was prescribed for IMRT: 70 Gy in 35 fractions (2 Gy per 
fraction) to GTV with 0.5-1.0 cm margin (CTV1), 63 Gy in 35 fractions 
(1.8 Gy per fraction) to high-risk CTV2, and 56 Gy in 35 fractions (1.6 
Gy per fraction) to the low-risk CTV3. A PTV margin of 5 mm was 
given to the respective CTV. The plan was normalized such that at 
least 95% of the volume of PTV1 to be covered by the 70 Gy isodose; 
no more than 20% of PTV1 to receive ≥77 Gy; and no more than 5% of 
PTV1 to receive ≥80.5 Gy. In addition, no more than 1% of any distinct 
PTV to receive ≤ 93% of the prescribed dose and no more than 1% of 
the tissue outside the PTV to receive ≥110% of the dose prescribed to 
PTV1. The treatment was delivered using 6 MV X-rays. Dose-volume 
histogram (DVH) was obtained for each of the 20 carotid arteries. 
Results: The median volume of the carotid artery was 6.2 cc (range, 
4.5-8.7 cc). The median of the mean dose to carotid artery was 58.4 
Gy (range, 53.3-64.3 Gy). The median of the maximum dose to carotid 
artery was 75.9 Gy (range, 61-79.1 Gy). The median and range of V40, 
V50, V60, and V70 were 5.7 cc (4.2-7.9 cc), 5.5 cc (4.1-7.8 cc), 3.8 cc 
(0.9-5.5 cc), and 1.2 cc (0.0-3.0 cc), respectively. With regard to the 
N0 cases, the median of mean and maximum dose to carotid artery 
was 58 Gy and 73.2 Gy respectively. The median of mean and 
maximum dose in N+ cases was 59.9 Gy and 77.3 Gy respectively.  
Conclusions: The dose heterogeneity in IMRT may contribute to 
increase in maximum dose to the carotid arteries. Long term clinical 
outcome may elucidate the risk of cerebrovascular events in patients 
treated with IMRT for oropharyngeal cancer.  
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Purpose/Objective: To compare the differences in resource utilisation 
between Cetuximab plus RT (EBRT) versus Cisplatin plus radiotherapy 
(CRT) taking in to account drug costs, clinical management and the 
costs of managing treatment related toxicity. Effects of treatment on 
quality of life, overall survival and local recurrence were also 
measured .  
Materials and Methods: 20 patients with stage 3 or 4 HNSCC were 
randomised between concomitant weekly Cetuximab or weekly 
Cisplatin plus XRT 70Gy in 35 fractions (10 Cetuximab, 10 Cisplatin). 
All drugs and hospital contacts were recorded to allow assessment of 
the health-economic impact of the management of toxicity additional 
to the initial cost of treatment. Data was collected for the acute 
phase, start of treatment to 6 weeks after completion of radiotherapy 
and late phase, from 6 weeks following completion of treatment to 6 
months following completion of treatment. Quality of life 
questionnaires were completed at baseline, at end of radiotherapy , 6 
weeks following completion of therapy and 6 months following 
completion of treatment. All patients have been followed up for 
greater than 24 months for survival and local recurrence rates. 
Biopsies have been retrospectively tested for p16 positivity by 
immunohistochemisty 
Results: Patients receiving Cisplatin required more intense 
management during the treatment and acute phase they were more 
likely to require overnight admission and required more laboratory 
and radiological investigation compared to those treatment with 
Cetuximab. Patients treated with Cisplatin also had more unplanned 
visits to hospital for management of the side effects of treatment. 
There was no significant difference between the two arm of the study 
for time spent with the head and neck CNS, Dietician or speech and 
language therapist. There were no differences in quality of life 
parameters between the 2 arms of the study although patients 
treatment with Cetuximab were significantly less likely to be using a 
feeding tube at 6 months. c2 p= 0.04. While the study was not 
powered to investigate differences in survival or local recurrence 
rates there was a statistically significant increase in local recurrence 
in patients treated by Cetuximab in this study. log rank p=0.014 
Conclusions: While the overall costs of drug treatment plus 
emergency admission are higher for Cetuximab when compared to 
Cisplatin terms patients undergoing Cisplatin and Radiotherapy 
require significantly more non routine intervention and care than 
patients receiving Cetuximab and Radiotherapy in this randomised 
study and this should be taken in to account when planned further 
trials. A study comparing cisplatin and Cetuximab to investigate 
quality of life and late functional effects of treatment could be viable 
within the NHS. Any future study should also be powered to 
investigate potential differences in overall survival and local 
recurrence rates 
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Purpose/Objective: To report our initial clinical experience of Helical 
Tomotherapy (HT) in the treatment of locally advanced oropharynx 
and inoperable oral cavity carcinoma, in terms of response, acute and 
late toxicity rates. 
Materials and Methods: Between February 2008 and January 2011, 24 
consecutive patients, 15 with oropharyngeal and 9 with oral squamous 
cell carcinoma were treated with exclusive radiotherapy or 
concomitant chemoradiotherapy. Simultaneous integrated boost (SIB) 
in 30 fractions scheme was prescribed to all patients, using Helical 
Tomotherapy. Patients treated with exclusive radiotherapy received a 
dose of 67.5 Gy in 2.25 Gy daily fractions for tumor and 63 Gy in 2.1 
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Gy daily fractions for oropharynx/oral cavity and positive lymph 
nodes. Lower doses were used for patients treated with concomitant 
chemotherapy: 66 Gy in 2.2 Gy daily fractions for tumor and 60 Gy in 
2 Gy daily fractions for oropharynx/oral cavity and positive lymph 
nodes. Negative lymph nodes were irradiated with equal dose for both 
groups: 54 Gy in 1.8 Gy daily fractions. Chemotherapy (either 
carboplatin 100mg/m2 or cisplatin 80 mg/m2) was given intravenously 
every 3 weeks. 
Results: The median follow-up was 24 months (range 3-53). Complete 
response rate for the oropharynx and the oral cavity group was 87% 
and 87.5% , respectively. The 1 and 2-year Overall Survival (OS) and 
Disease Free Survival (DFS) rate for the oropharynx group was 80%, 
73.3%, 73.3% and 73.3% respectively. For the oral cavity group, 1 and 
2-year OS and DFS rates were 62.5%. Concerning acute toxicity, no 
patient developed grade ≥3. G2 mucositis, dysphagia and dermatitis 
rates were 87%, 69.6% and 47.9%, respectively. Concerning late 
toxicity, maximum grade observed was G2 xerostomia in 5.6% of 
cases.  
Conclusions: HT appears to achieve encouraging clinical outcomes in 
terms of response, survival and toxicity rates.  
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Purpose/Objective: Incidence of Oral Cavity Squamous Cell 
Carcinoma (OCSCC) in India is amongst the highest in the world. The 
analysis highlights time lags in presentation and treatment along with 
disease control outcomes.  
Materials and Methods: Unselected case notes of 56 patients with 
OCSCC who underwent surgery at Tata Medical Center (TMC), between 
May 2011 to October 2012 were analysed. Time from presentation to 
consultation at TMC, consultation to first surgery, T, N, M and overall 
stage (AJCC 7) were analysed. Time lag between surgery to adjuvant 
treatment (radiotherapy (RT) or chemoradiotherapy (CTRT) to a dose 
of 60-63Gy in 30 fractions), disease free survival, distant metastases 
free survival, local recurrence and cases lost to follow up rates were 
calculated after a median follow up of 6 months. 
Results: The mean age was 52.9 years with 25 (44.6%) patients having 
oral tongue, 18 (32.14%) buccal mucosa disease. On presentation, 14 
(25%), 13 (23.2%), 23 (41%) and 5 (8.9%) patients had T4, T3, T2 and 
T1 disease respectively. 12 (21.4%), 15 (26.7%) and 5 (8.9%) had N1, 
N2 or N3 disease. 29 (51.7%), 16 (28.5%), 9 (16%) cases presented with 
stage IV, III and II disease. The time lag between first symptom to that 
when patient was seen in TMC was 4.5months (range 0-24 months). 5 
(8.9%) cases received neo adjuvant chemotherapy prior to surgery. 
Time lag between when seen at TMC and when surgery was performed 
was 1 month (range 0-3months) with 91% cases requiring some form of 
reconstructive procedure during surgery. Median time between 
surgery and adjuvant treatment was 1.5 months (range1-2 months). 27 
(48.2%) cases completed concurrent CTRT with a platinum agent, 26 
(46%) received RT only whist 2 patients refused to have RT and one 
received RT outside the country. 7 cases (12.5%) developed local 
recurrence. 4 (7.1%) cases developed distant metastases of which 
3(75%) developed both local and distant disease. 45 (80.3)% patients 
were alive at 6 months, 3 patients were lost to follow up. 4 deaths 
occurred within 1 month post treatment prior to any follow up and has 
been attributed to aspiration related symptoms. 
Conclusions: Indian patients present late, with more advanced 
disease at a younger age, majority with a significant time lag prior to 
presenting to the tertiary center. Although patients complete their 
treatment lack of community support could result in toxicities prior to 
the first follow up (1 month post RT) requiring early intervention by a 
community nurse. Early local or distant metastases in this patient 
group could raise the possibility of an aggressive biological subtype of 
OCSCC.  
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Purpose/Objective: To assess efficacy of geftinib along with 
chemoradiation (cisplatin + radiotherapy) in comparision to 
chemoradiation alone in management of locally advanced head and 
neck cancer. 
Materials and Methods: 60 previously untreated histologically proven 
patients of squamous cell carcinoma of head and neck cancer 
attending department of radiotherapy, SMS hospital, Jaipur from june 
2011 to may 2012 were taken and divided into two groups- control (30 
patients) and study (30 patients). The control group received cisplatin 
30mg/m2 iv weekly along with radiotherapy, starting from day 1 of 
radiotherapy. The study group received gefitinib 250 mg po starting 1 
week prior to commencement or radiotherapy followed by cisplatin 
30mg/m2 iv weekly along with radiotherapy, starting from day 1 of 
radiotherapy till its completion. Dose of radiotherapy was 66Gy/33Fr/ 
6.3 weeks. Patients were followed monthly upto 6 months. 
Results: The acute and late radiation toxicity on skin, mucosa and 
hemogram was variable in control and study groups but more in study 
group. Combined for all T stage tumors complete response (CR) for 
control and study groups was 24 (80%) and 17 (56%) respectively. The 
overall response (tumor+nodal response) for all stages was found 
statistically non-significant. Disease status at 6th month follow up in 
control and study group was: no evidence of disease- 21 (70%) versus 
27(90%), residual disease- 8 (27%) versus 3(10%). At the median follow 
up of 15 months, 16 patients of study group were on follow up,11 of 
which had complete response and 5 had recurrent disease. In control 
group, 10 patients were on follow up of which 7 had complete 
response and 3 had recurrent disease. 
Conclusions: Chemoradiation remains mainstay of treatment for head 
and neck carcinoma patients. EGFR is the most expressed receptor in 
squamous cell carcinoma of head and neck. The present study shows 
that targeted therapy with gefitinib (EGFR tyrosine kinase inhibitor) 
and chemoradiation is well tolerated with some enhanced but 
manageable toxicities and has shown to improve local control and 
survival in locally advanced head and neck cancer.  
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Purpose/Objective: The aim of the study was to analyze the overall 
outcomes, patterns of failure and toxicities of postoperative, daily 
image guided head and neck helical tomotherapy (HT). 
Materials and Methods: 86 patients (67 male and 19 female) were 
treated with HT between June 2007 and August 2010 at our 
institution. Overall, the median age was 58 years. The majority of 
patients had a T2(48%,n=41);N2(55%,n=47) tumor, with a total of 30 
patients with ECE. The median prescribed dose to the PTV was 64 Gy. 
42 patients underwent conconcomitant platinum based chemotherapy.  
Results: Median follow-up time was 32 months. 2-year (3-year) overall 
survival, disease-free survival, and locoregional control were 
81%(73%), 77%(63%), and 82%(74%), respectively. Overall 15 patients 
developed a locoregional failure (12 local, 3 regional): 14 infield , 1 
marginal field. 13 patients developed distant metastasis. At 2 years 2 
patients had grade 3 dysphagia (CTCAE v4.0). No further grade 3/4 
toxicitieswere observed. 
Conclusions: Our results show that daily image guided helical 
tomotherapy is effective and safe in terms of local disease control and 
avoidance of persistent grade 3/4 late toxicities. 
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Purpose/Objective: Radiation induced thyroid abnormality after 
radiotherapy (RT) of nasopharyngeal cancer (NPC) has been reported 
in many studies. Apart from the thyroid gland, the pituitary gland is 
also usually irradiated to high dose for patients with skull base 
involvement. Since the thyroid function is controlled by the pituitary 
gland through the hypothalamic-pituitary-thyroid axis, the hypothesis 
of this study was that the combined effect of high radiation dose to 
the thyroid and pituitary glands would increase the risk of thyroid 
abnormality.  
Materials and Methods: 65 NPC patients with stages II to IV treated by 
RT were recruited. Before RT, baseline thyroid hormone levels of each 
patient including fT3, fT4 and TSH were taken. A 7-beam intensity 
modulated radiotherapy (IMRT) plan was generated for each patient 
following the local planning protocol. The doses to the thyroid and 
pituitary glands were calculated by generating their dose volume 
histograms (DVH). The patients were divided into 4 categories 
according to the doses to the thyroid and pituitary glands, where 'high 
